Head-to-head · WeighScore
bmiMD vs REMEVi
By GLP-1 ScorecardUpdated
Score comparison
bmiMD has the higher recorded score — 79.2/100 to 73.5/100.
bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Before you choose
Before comparing the headline prices, the bmiMD review and the REMEVi review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, bmiMD vs Remote Pharmacy and CoreAge Rx vs REMEVi compare each of them with another graded program, and the list of alternatives to bmiMD ranks the programs closest to bmiMD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | bmiMD | REMEVi |
|---|---|---|
| WeighScore | 79.2/100 | 73.5/100 |
| Grade | C+ | C |
| Site position | #27 | #76 |
| Semaglutide | $129/mo on the one-month plan ($99/mo equivalent with $1,188 prepaid for 12 months) | $143/mo month-to-month ($96/mo on 12-month plan, $1,248 upfront; compounded) |
| Tirzepatide | $179/mo on the one-month plan ($139/mo equivalent with $1,668 prepaid for 12 months) | $224/mo month-to-month ($168/mo on 12-month plan, $2,184 upfront; compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- Advertises the same price across prescribed doses for each selected injection plan
- Publishes compounded semaglutide and tirzepatide injection plans
- Every rung of both ladders is published with the total charge beside each per-month figure
- All 50 states
What to consider
- The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
- The annual $99 and $139 monthly equivalents require $1,188 or $1,668 paid upfront for 12 months
- A higher $229 and $349 monthly figure is printed beside every plan price under a standing LIMITED TIME label, with no published basis
- Neither the compounding pharmacy nor the prescribing group is named on the product pages
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
What to consider
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Featured provider
bmiMD
Factor scores not reassessed.bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.